A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.

Sorry, there's nothing here.

Topics

Cite this paper

@article{Popat2013AP2, title={A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.}, author={Rakesh Popat and Torben Plesner and Faith Davies and Gordon Cook and Mark Cook and Peter Elliott and Eric S. Jacobson and Todd Gumbleton and Heather E. Oakervee and Jamie Cavenagh}, journal={British journal of haematology}, year={2013}, volume={160 5}, pages={714-7} }